Literature DB >> 7809176

Salicylates for ulcerative colitis--their mode of action.

S P Travis1, D P Jewell.   

Abstract

Delivery of 5-aminosalicylic acid to the colon by sulphasalazine, other azo-bonded compounds and controlled-release preparations is introduced in the context of metabolism by epithelial cells and therapeutic efficacy in ulcerative colitis. Potential modes of action are then reviewed, including actions on luminal bacteria, epithelial cell surface receptors, cellular events (such as nitric oxide release or butyrate oxidation), electrolyte transport and epithelial permeability. Evidence for an influence of salicylates on circulating and lamina propria inflammatory cells is presented, as well as actions on adhesion molecules, chemotactic peptides and inflammatory mediators, such as eicosanoids, platelet-activating factor, cytokines or reactive oxygen metabolites. The precise mechanism will remain uncertain as long as the aetiology of ulcerative colitis is unknown, but a pluripotential mode of action of salicylates is an advantage when influencing the network of events that constitute chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809176     DOI: 10.1016/0163-7258(94)90042-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  25 in total

1.  N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.

Authors:  Robert C Miller; Daniel G Petereit; Jeff A Sloan; Heshan Liu; James A Martenson; James D Bearden; Ronald Sapiente; Grant R Seeger; Rex B Mowat; Ben Liem; Matthew J Iott; Charles L Loprinzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-23       Impact factor: 7.038

2.  Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid.

Authors:  D Chen; G Radford-Smith; M C Dipaolo; I McGowan; D P Jewell
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

Review 3.  Human colonocyte detoxification.

Authors:  W E Roediger; W Babidge
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

Review 4.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

Review 5.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Fucosylated multiwalled carbon nanotubes for Kupffer cells targeting for the treatment of cytokine-induced liver damage.

Authors:  Richa Gupta; Neelesh Kumar Mehra; Narendra Kumar Jain
Journal:  Pharm Res       Date:  2013-09-17       Impact factor: 4.200

7.  Omega-3 fatty acids in the maintenance of ulcerative colitis.

Authors:  Cinzia Papadia; Alessandro Coruzzi; Chiara Montana; Francesco Di Mario; Angelo Franzè; Alastair Forbes
Journal:  JRSM Short Rep       Date:  2010-06-30

Review 8.  Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.

Authors:  Richard B R Muijsers; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 10.  Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.